Trials / Recruiting
RecruitingNCT07222137
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Baricitinib to Delay Stage 3 Type 1 Diabetes in At-risk Participants Aged ≥1 to <36 Years
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 1 Year – 35 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out if baricitinib can delay the onset of clinical type 1 diabetes (T1D) in people who are at high risk to develop T1D. Participation in the study will last up to approximately 5 years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Baricitinib | Administered orally |
| DRUG | Placebo | Administered orally |
Timeline
- Start date
- 2026-01-12
- Primary completion
- 2031-07-01
- Completion
- 2031-07-01
- First posted
- 2025-10-29
- Last updated
- 2026-04-17
Locations
107 sites across 18 countries: United States, Australia, Belgium, Brazil, Canada, Finland, France, Germany, Israel, Italy, Japan, Netherlands, Norway, Poland, Portugal, Spain, Sweden, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07222137. Inclusion in this directory is not an endorsement.